MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director of Drugs Control Administration in Rangareddy, Telangana.

Regulatory Action Details

The suspension order specifically targets one store situated at Vanasthalipuram Ganesh Temple in Telangana. The regulatory action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of approximately ₹1.19 lakhs due to the one-day suspension of the drug license.

Regulatory Compliance

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has fulfilled its obligation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the websites of BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on December 31, 2025.

Medplus Health Services has witnessed a significant reduction in pledged equity shares following a release transaction by Catalyst Trusteeship Limited. The debenture trustee released 41,71,970 pledged equity shares on December 24, 2025, marking a notable change in the company's encumbrance structure.

Share Release Details

Catalyst Trusteeship Limited, acting as Debenture Trustee on behalf of debenture holders, executed the release of pledged shares under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. The transaction involved the release of shares that were previously held as encumbrance.

Impact on Shareholding Pattern

The share release has resulted in a substantial reduction in the encumbered shareholding percentage. Prior to this transaction, Catalyst Trusteeship Limited held 1,07,98,429 shares under encumbrance, representing 9.01% of the total share capital.

Company Capital Structure

Medplus Health Services' equity structure remains stable despite the pledge release transaction. The company maintains its total equity share capital without any changes to the underlying share count or face value.

Current Capital Structure:

• Total Equity Share Capital: ₹23.96 crores
• Number of Equity Shares: 11,98,22,581
• Face Value per Share: ₹2.00
• Total Diluted Share Capital: ₹24.05 crores (12,02,53,747 shares)

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. Catalyst Trusteeship Limited submitted the required documentation to both NSE and BSE, ensuring full regulatory compliance for the share release transaction.

The transaction represents a standard debenture-related pledge release, with Catalyst Trusteeship Limited continuing to hold a reduced but significant encumbrance position in Medplus Health Services.